Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2004-09-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite the plethora of once-daily drugs available for the treatment of ADHD, physicians consistently prescribe immediate release formulations. To bolster revenues, manufacturers must continue to promote awareness of ADHD at all levels, but most also seek to further differentiate their once-daily products from generics and other branded products in the eyes of both the patient and the physician.


Scope

  • Analysis is based on a survey of 180 prescribing physicians in the seven major markets as well as in-depth interviews with ADHD Key Opinion Leaders
  • Detailed treatment trees showing the prevalence, diagnosis and treatment rates of ADHD across the seven major markets
  • Analyzes the first and second-line treatment of children and adolescents with ADHD
  • Identifies diagnostic and therapeutic unmet needs, highlights how manufacturers can drive patient identification as well as bolster drug prescriptions


    • Report Highlights
    Datamonitor primary research has identified variances in class- and brand-prescribing preferences among physicians, although prescribing trends generally follow recognized national and international guidelines. However, there is concern over the use of combination therapies in the absence of conclusive clinical trial data.

    Only 12.3% of patients are diagnosed, indicating that a huge proportion of patients remain undiagnosed and untreated. Although the awareness of ADHD is ever growing, there are still significant gaps between, knowledge, recognition and referral of the disease. Datamonitor has highlighted these and provides counteractive strategic recommendations.

    Only 20% of patients receive longer-acting, once-daily drugs at first-line, falling to 3% at second-line, with physicians preferring immediate-release formulations. Consequently, Datamonitor has identified numerous lifecycle strategies to bolster long-acting drug sales.


    Reasons to Purchase

  • Identify commercial opportunities by benchmarking current products and assessing unmet needs and future market potential
  • Assess the size of the drug-treated population through an understanding of the prevalence of ADHD with comorbid psychiatric and behavioral disorders
  • Communicate with physicians more effectively, through an understanding of prescribing behavior

    • Table of Contents

    Other users found this report page using the following search terms: adhd attention deficit adhd needs unmet japan line any adult diagnostic checklist germany

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.